Peptides and the Long Game: What Happens After Year One?

The Question No One Wants to Answer

Most protocols posted online describe an 8- or 12-week run. Some lifters use CJC-1295, ipamorelin or BPC-157 on and off for years, and the fair question is whether that carries costs that only show up later.

There are no 10-year controlled trials of these compounds in healthy adults. What we have is mechanism research, a few human studies lasting months to two years (mostly in patients, children or older adults), regulatory reviews and user reports. Each peptide class raises a different long-term question, so this page takes them one at a time. For background on the hormones involved, see how the growth hormone axis works.

GH Secretagogues: Are You Burning Out Your Pituitary?

This is the most common worry with long-term use of GHRH analogs (such as Mod GRF 1-29 and CJC-1295) and GHRPs (such as ipamorelin and GHRP-2). The pituitary responds to them through the growth hormone-releasing hormone receptor (GHRH-R) and the ghrelin receptor (GHSR). Under constant stimulation, receptors like these become less responsive, a process called desensitization.

The human data show partial fading rather than burnout:

• In a 1998 study, nine healthy young men received 100 mcg of GHRP-2 by daily subcutaneous injection for 5 days. Peak growth hormone (GH) fell from about 83 to 51 µg/L between day 1 and day 5. The response shrank but didn't stop.
• In a 2004 study of 17 older adults, a continuous 30-day subcutaneous GHRP-2 infusion still raised GH secretion more than 1.8-fold on days 14 and 30, and IGF-1 held at a stable plateau.
• In a small 1997 trial in children with short stature, intranasal GHRP-2 raised growth velocity from 3.7 to 6.1 cm/year at 6 months. The six children followed for 18-24 months kept that rate, and their acute GH responses didn't change.
• In a 2-year randomized trial of 65 healthy older adults, the oral ghrelin mimetic MK-677 (a small molecule, not a peptide) raised GH and IGF-1 into the young-adult range and kept them there.

The usual pattern is an early drop in response that settles at a lower but still elevated level. That's the reasoning behind the on/off schedules users describe, such as 5 days on and 2 off, or 8-16 weeks on and 4-8 weeks off (see the cycling schedules users describe). No study has compared those schedules with continuous use.

The compound matters too. In the 1998 swine studies that introduced it, ipamorelin released GH without raising cortisol, while GHRP-2 and GHRP-6 raised it. Whether that selectivity also means less desensitization hasn't been tested. CJC-1295 with DAC behaves differently from the short-acting peptides: in 2006 studies in healthy adults, a single injection raised GH for 6 days or more and IGF-1 for 9-11 days, closer to a sustained elevation than a pulse. FDA's compounding safety page lists serious adverse events reported with CJC-1295, including increased heart rate and a systemic vasodilatory reaction.

The IGF-1 and cancer question

Raising GH raises insulin-like growth factor 1 (IGF-1), which promotes cell growth in muscle and other tissues. The concern isn't that peptides cause cancer, but that sustained high IGF-1 could help an existing, undiagnosed tumor grow.

The human evidence is indirect. A 2004 meta-analysis in The Lancet (21 studies, 3,609 cancer cases) found that people with naturally higher IGF-1 had a modestly higher risk of prostate and premenopausal breast cancer, with odds ratios of about 1.5 to 1.65 comparing the 75th with the 25th percentile. Those are associations within the normal population range. Nobody has measured cancer rates in people using research peptides.

A 2018 review argues that secretagogues trigger pulsatile GH release that stays under the body's negative feedback, which may avoid the sustained high levels seen with injected GH. That's a mechanistic argument; the same review says long-term data on cancer incidence and mortality are still needed.

Tesamorelin: the closest thing to long-term data

Tesamorelin, a GHRH analog, is a prescription medicine (Egrifta) approved in the US to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. In a pooled analysis of two Phase 3 trials (806 patients, 26 weeks plus a 26-week safety extension), IGF-1 rose by about 108 ng/mL on average, the drug was generally well tolerated, and glucose measures didn't change meaningfully over 52 weeks.

Its prescribing information is still cautious: it states that "the effects of prolonged elevations in IGF-1 levels are unknown," rules out use in active malignancy, and says long-term cardiovascular safety hasn't been established. One supervised year says little about a decade of self-directed use, and research-grade products aren't the approved medicine (see peptide legal and regulatory status).

The Healing Peptide Paradox: BPC-157 and Angiogenesis

For BPC-157 and TB-500, the long-term concern is angiogenesis, the formation of new blood vessels, rather than hormonal fatigue.

In a 2017 study, BPC-157 increased vessel density and sped blood-flow recovery in rats with hind-limb ischemia, and raised expression of VEGF receptor 2 (VEGFR2) in endothelial cells. New vessels bring nutrients and repair cells to an injury, which is one proposed explanation for faster healing in animal studies.

The theoretical risk is that the same signaling could feed a small, undiagnosed tumor. A 2025 narrative review lists pathologic angiogenesis among BPC-157's proposed side effects, while also citing animal studies in which it suppressed VEGF-driven tumor growth. The Zagreb group that first described the peptide reported in 2009 that it had no direct angiogenic effect in cell culture but "adequately modulated" angiogenesis in healing rat muscle and tendon, which is why its developers describe it as acting mainly at injury sites.

What's missing is long-term data. A 2025 systematic review found 36 studies, 35 of them preclinical, and "no clinical safety data." The animal safety studies it describes ran for up to 6 weeks, too short to detect slow-growing tumors, so the absence of tumor reports in animals says little about long-term safety.

TB-500 is often called thymosin beta-4, but it's a synthetic 7-amino-acid fragment (Ac-LKKTETQ) of that protein. As of October 2026, FDA's compounding safety page says the agency has not identified any human exposure data for the fragment. Full-length thymosin beta-4 promotes cell migration in lab studies, and what years of repeated use do is unknown. Most user protocols treat both peptides as short-term tools for a specific injury, commonly 4-8 weeks, rather than ongoing "injury insurance." That's the more cautious pattern, though it hasn't been tested either.

Melanotan II: Changes You Can See

Melanotan II (MT-II), a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH), is used mainly for tanning. Unlike most peptides here, some of its long-term effects are visible: it darkens existing moles and freckles and can bring out new ones.

A 2017 dermatology review described growing numbers of case reports linking unregulated melanotan use to changes in existing moles and new dysplastic nevi, plus four reports of melanoma arising from existing moles during or shortly after use. The authors note that conclusive evidence of a causal link is lacking. A 2025 case report described oral mucosal melanoma after MT-II nasal spray, and FDA's compounding safety page cites case reports of melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism.

A tan fades, but new moles may not, and they make skin checks harder because change in a mole is a key melanoma warning sign.

A Framework for Long-Term Cycling

The durations below reflect common community practice, not tested protocols.

AOD-9604 is sometimes called one of the safer options for long runs because it doesn't raise IGF-1, and FDA's December 2024 advisory committee briefing says the human studies reported no significant IGF-1 change. But those trials used oral or IV dosing, not the subcutaneous injections users describe, mostly showed no weight loss beyond placebo, and no carcinogenicity studies exist. FDA found "insufficient information to support patient safety for the long-term use" of AOD-9604.

Blood Work: Your Only Objective Map

Beyond a single run, blood work is the only objective view of what a peptide is doing. The markers that matter most for GH-related peptides overlap with what doctors monitor during approved treatment:

• IGF-1: shows the downstream effect of a secretagogue. A level well above the age-adjusted range, toward acromegaly territory, is a warning sign. Tesamorelin's label calls for IGF-1 monitoring and considering stopping if it stays elevated.
• Fasting glucose and HbA1c: growth hormone reduces insulin sensitivity. In the MK-677 trial, fasting glucose rose by about 5 mg/dL, and the 2018 review names rising blood glucose as the main safety concern with secretagogues.
• Prolactin and cortisol: GHRP-2, GHRP-6 and hexarelin raised cortisol in human studies, usually transiently, and some secretagogues also raised prolactin. Chronically high prolactin can lower libido.
• Comprehensive metabolic panel (CMP) and complete blood count (CBC): routine checks of liver enzymes, kidney function and blood cells.

The same numbers show whether a protocol does anything: if IGF-1 hasn't moved after 12 weeks of a secretagogue, the dose may be too low or the vial may not contain what its label says.

What we still don't know

As of October 2026, nobody can offer a 20-year safety record for these compounds. The open questions are specific:

• Whether years of pulsed secretagogue use, with breaks, changes cancer risk. No study has measured it.
• Whether on/off cycling preserves the GH response better than continuous use. No one has compared schedules directly.
• Whether BPC-157's effects on blood vessels matter away from an injury over months or years. A University of Arkansas placebo-controlled pilot in rotator cuff repair (90 days of daily subcutaneous injections) is registered with a planned January 2027 start and was not yet recruiting as of October 2026.
• What's actually in gray-market vials, which affects every risk estimate on this page.